Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
18 Years
N/A
Male
Prostate Cancer
Trial Information
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
OBJECTIVES:
Primary
- Demonstrate the feasibility of acquiring specimens, both frozen and paraffin-embedded,
to yield RNA of adequate quality to perform DNA microarray studies on markers of
radiotherapy outcome in patients with intermediate-risk prostate cancer.
Secondary
- Compare the gene expression results from frozen tissue and paraffin-embedded tissue to
see the correlation between the 2 methods in patients treated on the brachytherapy
alone arm of protocol RTOG-0232.
- Find genes that are expressed differentially before and after radiation therapy in
patients treated on the brachytherapy plus external-beam radiation therapy arm of
protocol RTOG-0232.
- Find gene expression patterns in patients treated on either arm of protocol RTOG-0232
who have significant associations with biochemically as well as clinically apparent
local and distant failure.
OUTLINE: This is a multicenter, pilot study.
Frozen and paraffin-embedded tissue samples are studied for biomarker/laboratory analysis.
DNA microarray analysis is performed on the samples to assess markers of radiotherapy
outcome.
PROJECTED ACCRUAL: A total of 156 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of prostate cancer
- Stage II disease
- Adenocarcinoma
- Eligible for and enrolled on protocol RTOG 0232
- Able to submit frozen tissue cores from biopsy specimens obtained at the time of
brachytherapy
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- No prior neoadjuvant hormonal therapy
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Number of frozen and paraffin-embedded specimens that yield adequate RNA for tumor tissue microarray analysis
Safety Issue:
No
Principal Investigator
Arnab Chakravarti, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Ohio State University
Authority:
United States: Federal Government
Study ID:
CDR0000490025
NCT ID:
NCT00899912
Start Date:
June 2006
Completion Date:
Related Keywords:
- Prostate Cancer
- stage IIB prostate cancer
- stage IIA prostate cancer
- adenocarcinoma of the prostate
- Prostatic Neoplasms
Name | Location |
|---|---|
| Winship Cancer Institute of Emory University | Atlanta, Georgia 30322 |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St. Louis, Missouri 63110 |
| Fox Chase Cancer Center - Philadelphia | Philadelphia, Pennsylvania 19111-2497 |
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | Columbus, Ohio 43210-1240 |
| MedCentral - Mansfield Hospital | Mansfield, Ohio 44903 |
| Cancer Institute at St. John's Hospital | Springfield, Illinois 62701 |
| Georgia Cancer Center for Excellence at Grady Memorial Hospital | Atlanta, Georgia 30303 |
| Emory Crawford Long Hospital | Atlanta, Georgia 30308 |
| Barnes-Jewish West County Hospital | Saint Louis, Missouri 63141 |
| Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters | Saint Peters, Missouri 63376 |
